By: Elai Katz, Lisa P. Rumin & Betty Zhang (McDermott Will & Emery Antitrust Alert)
Pharmaceutical patent holders take note: Over the past year, antitrust enforcers have intensified their scrutiny of Orange Book listings, viewing them as potentially anticompetitive. The Federal Trade Commission has stated that improperly listing patents in the Orange Book can constitute an unfair method of competition, among other legal violations.
In this article, Elai Katz, Lisa Rumin, and Betty Zhang examine this increased focus on Orange Book listings and outline the risks brand-name drug manufacturers should be mindful of regarding their listing practices. Moving forward, these manufacturers should adopt a proactive approach by thoroughly documenting their evaluation process and the rationale behind listing patents in the Orange Book to ensure compliance with statutory requirements…
Featured News
Court Dismisses Monopoly Claims Against Tempur Sealy
Oct 18, 2024 by
CPI
Philadelphia City Council Advances Legislation to Tackle Rent Price-Fixing
Oct 17, 2024 by
CPI
FTC Probes Deere for Potential Anti-Competitive Repair Practices
Oct 17, 2024 by
CPI
Britain’s Ofcom to Outline Strict Guidelines for Tackling Illegal Online Content
Oct 17, 2024 by
CPI
EU Considers Expanding Potential Fines for X, Targeting Musk’s Broader Business Empire
Oct 17, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh